256 related articles for article (PubMed ID: 21166701)
41. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
[TBL] [Abstract][Full Text] [Related]
42. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
43. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
44. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
45. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
46. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
47. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
48. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
50. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
51. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
[TBL] [Abstract][Full Text] [Related]
52. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
53. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
54. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
55. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
56. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
57. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
58. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
59. Low expression of bcl-2 in Brca1-associated breast cancers.
Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
